Abstract: The present invention relates to a reflector for an acoustic shock or pressure wave head, wherein the reflector comprises an acoustically reflective surface formed by a body of rotation, said body of rotation being formed by rotation of an elliptical segment about a rotation axis which extends through a focal point of the ellipse and encloses an angle ? between 0.1° and 30° with the main axis of the ellipse.

Abstract: The present invention relates to a single-use test-strip for the quantitative determination of sodium concentration and creatinine concentration and for the subsequent determination of their ratio, and to a non-invasive point-of-care (POC) device for detecting sodium depletion and/or sodium overload in a patient's body. Furthermore, the present invention relates to a method for simultaneously and quantitatively determining sodium concentration and creatinine concentration in a patient's urine sample and to a method of detecting sodium depletion and/or sodium overload in a patient's body.

Abstract: The present invention relates to a method of site-directed integration into a genetic locus encoding at least one activity of the pyrimidine salvage pathway in a host cell, wherein said activity of the pyrimidine salvage pathway is purine/cytosine permease (FcyB), cytosine deaminase (FcyA), uracil-phosphoribosyl-transferase (Uprt), concentrative nucleoside transporter (CntA) or uridine kinase (UK), comprising: a) providing a host cell comprising a functional copy of the genetic locus encoding at least one activity of the pyrimidine salvage pathway; (b) introducing a gene or sequence of interest into said host cell via transformation of an integrative nucleic acid construct which comprises 3? and/or 5? of the gene or sequence of interest flanks being homologous to said genetic locus or which carries a sequence being homologous to said genetic locus of the pyrimidine salvage pathway and thus allowing for a homologous recombination at said genetic locus, wherein said homologous recombination is capable of causin

Abstract: The present invention relates to a reflector for an acoustic shock or pressure wave head, wherein the reflector comprises an acoustically reflective surface formed by a body of rotation, said body of rotation being formed by rotation of an elliptical segment about a rotation axis which extends through a focal point of the ellipse and encloses an angle ? between 0.1° and 30° with the main axis of the ellipse.

Abstract: The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones, such as for example, N-{4-[1-(2,6-dichloro-4-sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl]-phenyl}-2-diethylamino-acetamide, particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore, the present invention relates to processes for the synthesis of said 3-aminopyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.

Abstract: The present disclosure relates to an intraoral suctioning device for intraoral negative pressure wound treatment and a method for manufacturing the same. In order to permanently maintain the negative pressure in a wound with a view to an improved wound treatment and regeneration process, the intraoral suctioning device for the intraoral negative pressure wound treatment as disclosed can include a dental splint, an elastic membrane sealing an aperture formed in the dental splint so as to define a sealed wound treatment area on the inside of the dental splint, and a suctioning channel system for evacuating the wound treatment area.

Abstract: A registration device for patient registration comprises at least one reference marker adapted to be sensed by an imaging system and/or at least one position element adapted to be localized by a position sensing system, and fixation element for positioning the registration device in a patient's body cavity at a location comprising soft tissue. The registration device is adapted to be introduced into and positioned in the patient's body cavity, particularly in the viscerocranium such as the nasal cavity, the nasopharynx, the ear canal(s) and/or the neurocranium such as a cerebral ventricle.

Abstract: The present disclosure relates to an intraoral suctioning device for intraoral negative pressure wound treatment and a method for manufacturing the same. In order to permanently maintain the negative pressure in a wound with a view to an improved wound treatment and regeneration process, the intraoral suctioning device for the intraoral negative pressure wound treatment as disclosed can include a dental splint, an elastic membrane sealing an aperture formed in the dental splint so as to define a sealed wound treatment area on the inside of the dental splint, and a suctioning channel system for evacuating the wound treatment area.

Abstract: The present invention relates to a predictive diagnostic method for identifying whether a patient will develop metabolic syndrome and/or type-2 diabetes in the future. In particular, the invention relates to a method for identifying a subject which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e. determining/measuring/quantifying) in a sample obtained from a test subject the amount of miR-122; and (b) identifying (i.e. detecting) a subject, which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein an increased amount of miR-122 as compared to the amount of miR-122 of a healthy reference population indicates a risk for developing metabolic syndrome and/or type-2 diabetes. Another aspect of the invention relates to a method for monitoring the therapeutic success during the treatment of metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e.

Abstract: Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a secon

Abstract: A registration device (1) for patient registration comprises at least one reference marker (2) adapted to be sensed by an imaging system (5) and/or at least one position element (3) adapted to be localized by a position sensing system (6), and fixation means (4) for positioning the registration device (1) in a patient's body cavity at a location comprising soft tissue. The registration device (1) is adapted to be introduced into and positioned in the patient's body cavity, particularly in the viscerocranium such as the nasal cavity, the nasopharynx, the ear canal(s) and/or the neurocranium such as a cerebral ventricle.

Abstract: The present invention relates to methods of determining intracellular Cbl-b protein in cells of a sample, comprising introducing an antibody, which binds Cbl-b intracellularly, into a cell, allowing contracting of the antibody and Cbl-b protein potentially present in the cell, detecting binding events between the antibody and Cbl-b, quantifying the detected binding events, whereby the content of Cbl-b protein is determined.

Abstract: The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.

Abstract: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.